Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

Summary

This NIH funding opportunity (PAR-25-266) solicits R21 exploratory/developmental research grant applications focused on innovative screening approaches and therapies for screenable disorders in newborns. The R21 mechanism supports early-stage, high-impact research with clinical trial activity optionally permitted. The opportunity is posted by the National Institutes of Health (HHS-NIH11) and remains open for submissions through November 2027, allowing multiple submission cycles.

How they evaluate

Risks & flags

• No dollar values or budget caps are stated in the available text — award size and scoring criteria cannot be assessed for wiring
• Long open window (3 years) is standard for NIH Program Announcement with Review (PAR) mechanisms — not a red flag in itself